Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$0.65.

  • Stoke Therapeutics' EPS (Basic) fell 3829.79% to -$0.65 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.73, marking a year-over-year increase of 13476.19%. This contributed to the annual value of -$1.64 for FY2024, which is 3107.19% up from last year.
  • Stoke Therapeutics' EPS (Basic) amounted to -$0.65 in Q3 2025, which was down 3829.79% from -$0.4 recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' EPS (Basic) peaked at $1.95 during Q1 2025, and registered a low of -$0.69 during Q2 2023.
  • Moreover, its 4-year median value for EPS (Basic) was -$0.57 (2024), whereas its average is -$0.39.
  • Data for Stoke Therapeutics' EPS (Basic) shows a peak YoY increase of 44210.53% (in 2025) and a maximum YoY decrease of 3829.79% (in 2025) over the last 5 years.
  • Over the past 4 years, Stoke Therapeutics' EPS (Basic) (Quarter) stood at -$0.65 in 2022, then rose by 5.59% to -$0.61 in 2023, then soared by 67.77% to -$0.2 in 2024, then plummeted by 228.61% to -$0.65 in 2025.
  • Its EPS (Basic) was -$0.65 in Q3 2025, compared to -$0.4 in Q2 2025 and $1.95 in Q1 2025.